Spruce Biosciences (SPRB) Cash from Operations (2019 - 2026)
Spruce Biosciences (SPRB) posted quarterly Cash from Operations of 8732000.0 for Q1 2026, up 31.39% year-over-year from 6645865.57 in Q1 2025, and down 236.44% quarter-over-quarter from 6400000.0 in Q4 2025.
Spruce Biosciences (SPRB) Cash from Operations (2019 - 2026) Analysis & Trends
Spruce Biosciences (SPRB) has reported Cash from Operations for 8 consecutive years, with 8732000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Cash from Operations rose 31.39% year-over-year to 8732000.0; the TTM figure through Mar 2026 stood at 37295000.0 (up 169.41% YoY), while the FY2025 annual figure was 33300000.0, up 159.5% from the prior year.
- Cash from Operations eased to 8732000.0 in Q1 2026 per SPRB's latest filing, from 6400000.0 in the prior quarter.
- Across five years, Cash from Operations topped out at 48455000.0 in Q3 2025 and bottomed at 20677000.0 in Q4 2024.
- Historically, Cash from Operations has averaged 6256117.65 across 5 years, with a median of 11106000.0 in 2024.
- Annual changes were most pronounced in 2024 — Cash from Operations plunged 657.25% — and 2025, when it surged 625.37%.
- Spruce Biosciences' Cash from Operations stood at 11738000.0 in 2022, then grew by 4.51% to 11209000.0 in 2023, then slumped by 84.47% to 20677000.0 in 2024, then surged by 130.95% to 6400000.0 in 2025, then tumbled by 236.44% to 8732000.0 in 2026.
- Business Quant data shows SPRB's Cash from Operations at 8732000.0 in Q1 2026, 6400000.0 in Q4 2025, and 48455000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Ops. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.03 Bn | 131.18 Bn | 2.84 Bn | 1.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.64 Bn | 77.64 Bn | 3.93 Bn | 813.00 Mn |
| 3 | Argenx Se | 64.93 Bn | 59.75 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.93 Bn | 52.80 Bn | 52.00 Mn | -526.00 Mn |
| 5 | BeOne Medicines | 41.95 Bn | 36.86 Bn | 1.53 Bn | 462.82 Mn |
| 6 | Alnylam Pharmaceuticals | 31.51 Bn | 28.20 Bn | 992.69 Mn | 326.72 Mn |
| 7 | BioNTech SE | 28.00 Bn | 9.60 Bn | 668.28 Mn | 360.27 Mn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | -88.83 Mn |
| 9 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - | 728.46 Mn |
| 10 | Spruce Biosciences | 119.20 Mn | 119.20 Mn | - | 39.63 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 39.63 Mn |
| Jun 30, 2026 | 39.63 Mn |
| Mar 31, 2026 | -8.73 Mn |
| Mar 31, 2026 | -8.73 Mn |
| Dec 31, 2025 | 6.40 Mn |
| Dec 31, 2025 | 6.40 Mn |
| Sep 30, 2025 | 48.46 Mn |
| Sep 30, 2025 | 48.46 Mn |
| Jun 30, 2025 | -8.83 Mn |
| Jun 30, 2025 | -8.83 Mn |
| Mar 31, 2025 | -12.73 Mn |
| Mar 31, 2025 | -12.73 Mn |
| Dec 31, 2024 | -20.68 Mn |
| Dec 31, 2024 | -20.68 Mn |
| Sep 30, 2024 | -9.22 Mn |
| Sep 30, 2024 | -9.22 Mn |
| Jun 30, 2024 | -11.11 Mn |
| Jun 30, 2024 | -11.11 Mn |
| Mar 31, 2024 | -14.96 Mn |
| Mar 31, 2024 | -14.96 Mn |